JRSIS HEALTH CARE (JRSS) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	JRSIS HEALTH CARE Corp
Entity Central Index Key	1597892
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$0
Trading Symbol	CIK0001597892
Entity Common Stock, Shares Outstanding		13,915,000

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$1,046,485	$631,288
Accounts receivable, net	661,665	271,427
Inventories	180,630	98,300
Other receivables	1,755	2,699
Prepayments	691,802	61,572
Advance to related parties	185,391	180,930
Deposits for capital leases - current portion	92,630	19,300
Total current assets	2,860,358	1,265,516
Construction in progress	0	15,346,873
Property and equipment, net	20,331,864	1,416,732
Deposits for capital leases	677,013	490,677
Total assets	23,869,235	18,519,798
Current Liabilities:
Accounts payable	291,097	84,469
Short-term bank loans	471,277	0
Deposits received	6,526	9,208
Due to related parties	1,297,036	0
Other payable	71,562	18,569
Payroll payable	30,808	26,975
Capital lease obligations - current portion	807,478	211,459
Total current liabilities	2,975,784	350,680
Capital lease obligations	15,903,211	15,024,218
Total liabilities	18,878,995	15,374,898
Shareholders' equity
Common stock; $0.001 par value, 100,000,000 shares authorized; 13,604,000 and 12,000,000 issued and outstanding at December 31, 2014 and December 31, 2013, respectively	13,604	12,000
Additional Paid-in capital	954,686	38,000
Retained earnings	1,011,471	399,977
Other comprehensive income	14,045	23,859
Total shareholders' equity of the Company	1,993,806	473,836
Non-controlling interest	2,996,434	2,671,064
Total shareholders' equity	4,990,240	3,144,900
Total liabilities and shareholders' equity	$23,869,235	$18,519,798

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Common Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	13,604,000	12,000,000
Common Stock, Shares, Outstanding	13,604,000	12,000,000

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Medicine	$2,937,981	$2,084,492
Patient services	3,041,629	2,266,744
Total revenue	5,979,610	4,351,236
Operating costs and expenses:
Cost of medicine sold	1,735,300	1,247,915
Medical consumables	451,394	307,493
Salaries and benefits	1,176,798	890,780
Office supplies	100,998	65,472
Vehicle expenses	35,348	60,353
Utilities expenses	62,367	67,474
Rentals and leases	153,568	165,667
Advertising and promotion expenses	2,651	5,344
Interest expense	1,011,476	12,765
Professional fee	156,444	93,776
Depreciation	175,303	116,378
Total operating costs and expenses	5,061,647	3,033,417
Earnings from operations before other income and income taxes	917,963	1,317,819
Other income	25,299	6,857
Earnings from operations before income taxes	943,262	1,324,676
Income tax	2,157	1,984
Net income	941,105	1,322,692
Less: net income attributable to non-controlling interests	329,611	922,715
Net income attributable to the Company	611,494	399,977
Other comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests	-4,241	37,927
Foreign currency translation adjustment attributable to the Company	-9,814	23,859
Comprehensive income	927,050	1,384,478
Less: Comprehensive income attributable to non-controlling interests	325,370	960,642
Comprehensive income attributable to the Company	$601,680	$423,836
Basic and diluted earnings per share (in dollars per share)	$0.05	$0.29
Weighted average number of shares outstanding basic and diluted (in shares)	13,494,129	1,380,822

CONSOLIDATED_STATEMENT_OF_SHAR

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (USD $)	Total	Common Stock	Retained Earnings	Other Comprehensive Income	Additional Paid-in Capital	Noncontrolling Interest
Balance at Dec. 31, 2012	$1,007,914	$0	$0	$0	$0	$1,007,914
Balance (in shares) at Dec. 31, 2012		0
Net income	1,322,692	0	399,977	0	0	922,715
Paid-in capital	702,508	0	0	0	0	702,508
Stock Exchange Merger & Acquisition	50,000	12,000	0	0	38,000	0
Stock Exchange Merger & Acquisition (in shares)		12,000,000
Foreign currency translation adjustment	61,786	0	0	23,859	0	37,927
Balance at Dec. 31, 2013	3,144,900	12,000	399,977	23,859	38,000	2,671,064
Balance (in shares) at Dec. 31, 2013		12,000,000
Net income	941,105	0	611,494	0	0	329,611
Stock Exchange Merger & Acquisition	918,290	1,604	0	0	916,686	0
Stock Exchange Merger & Acquisition (in shares)		1,604,000
Foreign currency translation adjustment	-14,055	0	0	-9,814	0	-4,241
Balance at Dec. 31, 2014	$4,990,240	$13,604	$1,011,471	$14,045	$954,686	$2,996,434
Balance (in shares) at Dec. 31, 2014		13,604,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net income	$941,105	$1,322,692
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	175,303	116,378
Interest	1,007,743	0
(Gain) / loss on disposal of fixed assets	-15,363	5,959
Changes in operating assets and liabilities:
Accounts receivable, net	-392,318	-57,653
Inventories	-83,033	-35,360
Prepayments and other current assets	20,982	37,843
Accounts payable	216,686	37,023
Due to related parties	178,700	-417,976
Deposits received	-2,625	3,000
Accrued expenses and other current liabilities	7,003	-18,692
Net cash provided by operating activities	2,054,183	993,214
Cash Flows From Investing Activities
Purchases of fixed assets	-3,593,370	-701,504
Prepayment for fixed assets acquisition	-651,816	-42,916
Proceeds from disposal of fixed assets	65,060	95,351
Net cash used in investing activities	-4,180,126	-649,069
Cash Flows From Financing Activities
Proceeds from non-controlling shareholder	0	702,670
Proceeds from shareholders	918,290	0
Payments on capital lease obligation	-1,593,231	-627,659
Proceeds due to related parties	1,114,145	0
Short-term bank loans	471,682	0
Proceeds from finance lease	1,626,490	0
Net cash provided by financing activities	2,537,376	75,011
Effect of exchange rate fluctuation on cash and cash equivalents	3,764	11,657
Net increase in cash and cash equivalents	415,197	430,813
Cash and cash equivalents, beginning of period	631,288	200,475
Cash and cash equivalents, ending of period	1,046,485	631,288
Supplemental disclosure of cash flow information
Cash paid for income taxes	-2,157	-1,984
Cash paid for interest	-1,007,743	-11,539
Non-cash investing and financing activities:
Purchases of fixed assets under capital lease obligations	$269,765	$15,185,032

DESCRIPTION_OF_BUSINESS_AND_OR

DESCRIPTION OF BUSINESS AND ORGANIZATION	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION
	JRSIS HEALTH CARE CORPORATION (the “Company” or “JHCC”) was incorporated on November 20, 2013 under the laws of the United States and the State of Florida. The general nature of the business shall be to engage in any and all lawful business permitted under the laws of the United States and the State of Florida.
	JRSIS HEALTH CARE LIMITED ("JHCL"), formly named China Runteng Medical Group Co., Ltd, which is a privately held Limited Liability Company registered in British Virgin Island (“BVI”) on February 25, 2013. JHCL was authorized to issue 50,000 shares of a single class each with par value of $1.00 per share to its sole shareholder Ms. Yanhua Xing. On November 20, 2013, China Runteng Medical Group Co., Ltd has changed its name to JRSIS HEALTH CARE LIMITED ("JHCL").
	Runteng Medical Group Co., Ltd (“Runteng”) is a privately held limited liability company registered in Hong Kong on September 17, 2012. Runteng was authorized to issue up to 10,000 shares with par value of HK$1 per share to its sole shareholder Ms. Yanhua Xing.
	Harbin Jiarun Hospital Co., Ltd (“Jiarun”) was a privately held, for-profit hospital, incorporated in Harbin city of Heilongjiang, China in February 2006. Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. After a series of share exchanges mentioned here after in note 1, Jiarun became a 70% owned subsidiary of the Company.
	JHCC, JHCL, Runteng and Jiarun are collectively referred as the “Group”. The Group provides full health care services in the Heilongjiang region in China through Jiarun, its 70% owned subsidiary.
	In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, “Consolidation”, the consolidated financial statements presented herein include the accounts of JHCC, JHCL, Runteng and its 70% owned subsidiary, Jiarun.
	Reorganization
	On December 23, 2012, in accordance with the "Foreign Investment Enterprise Law" under the People’s Republic of China (“PRC”), Runteng and Jiarun entered into an agreement that Runteng and the original owner of Jiarun should invest a total of $7,936,508(equivalent to RMB50,000,000), in which Runteng and the original owner should contribute $5,555,556 (equivalent to RMB35,000,000)or 70% and $2,380,952 (equivalent to RMB15,000,000) or 30% of the total capital, respectively. According to the Article of Association (Joint venture investment agreement) and the amending of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay $5,555,556 (RMB35,000,000) within five years after the issuance of the joint venture business license. As of December 31, 2014, Jiarun has received $921,000 from Runteng.
	On July 08, 2014, Jiarun obtained joint venture business license. Runteng has already completed “cooperation restructuring”. Up to completion of the legal structures, Jiarun are compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.
	On February 25, 2013, JHCL issued 50,000 authorized shares to its sole shareholder Ms. Yanhua Xing. After the issuance, the total shares issued by JHCL were 50,000 with par value of US$1.00 per share.
	On March 7, 2013, JHCL acquired all 100 issued and outstanding shares of through share exchanges to obtain 100% controlling interests of Runteng.
	On June 01, 2013, Junsheng Zhang, the owner of Jiarun, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In which, the historical accumulated profit of Jiarun up to June 30, 2013 should be 100% attributed to Junsheng Zhang; the profit generated from Jiarun after July 1, 2013 should be attributed to Runteng and Junsheng Zhang on the basis of 70% and 30%, respectively.
	On July 29, 2013, the Joint Venture Investment Agreement between Runteng and Junsheng Zhang has been approved by the Development and Reform Commission of Hulan District, Harbin City and Harbin Investment Promotion Bureau. On the same date, Jiarun has obtained Certificate of Approval for Establishment of Enterprises with Investment of Taiwan, Hong Kong, Macao and Overseas Chinese in the People’s Republic of China; the Joint Venture Jiarun duration of operation is twenty years.
	Runteng would pay to Jiarun as soon as Runteng obtain funding from any alternatives. On July 08, 2014, Jiarun obtained joint venture business license. Runteng has already completed “cooperation restructuring”. According to the amending of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay $5,555,556 (35M RMB) within five years after the issuance of the joint venture business license.
	On October 3, 2013, Ms. Yanhua Xing transferred 23,275 JHCL shares to Mr. Junsheng Zhang, 23,225 JHCL shares to Ms. Chunlan Tang, and 1,050 JHCL shares to Mr. Weiguang Song.
	On November 8, 2013, Ms. Chunlan Tang transferred all 23,225 JHCL shares to Mr. Junsheng Zhang, subsequently making Mr. Junsheng Zhang holdings 46,500 JHCL shares.
	On December 20, 2013, a share exchange agreement was entered by and among JHCC, JHCL and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song. JHCC desires to issue a total of 12,000,000 shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in exchange for one hundred percent (100%) of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC a total of 50,000 shares of the ordinary share of JHCL which represents one hundred percent (100%) of the issued and outstanding shares of JHCL. JHCL shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and an assets of JHCL as now or hereafter existing, including all business and assets of any and all subsidiaries of JHCL, including Seventy percent (70%) ownership interest in Jiarun, the operating company in PRC through JHCL wholly holds subsidiary, Runteng, a Hong Kong registered investment company.
	Before and after the reorganization mentioned above, Junsheng Zhang continued to serve as chairman of Jiarun (the “Operating Subsidiary”), and together with the other management of the Company, continued to direct both day-to-day operation and management of the Operating Subsidiary, as well as its strategic direction. The reorganization effectively resulted in Junsheng Zhang continuing to bear the residual risks and rewards related to the Operating Subsidiary. Because of the reasons described above, the Company is substantively controlled by Junsheng Zhang, and the Company continued to consolidate the Operating subsidiary during the reorganization. And the reorganization transactions are considered as a series of transactions between the parties under common control and did not establish a new basis in the assets and liabilities of the Operating Subsidiary.
	As a result, during the reorganization, JHCC, JHCL, Runteng and Jiarun were under common control of Junsheng Zhang. Therefore, the reorganization was effectively a legal recapitalization accounted for as transactions between entities under common control at the carry over basis, in a manner similar to pooling-of-interests accounting. The effect of the reorganization was applied retroactively to the prior years’ consolidated financial statements as if the current structure existed since inception.
	30% of Jiarun hospital interest held by Junsheng Zhang is subjecting to non-controlling interest (“NCIs”), which was stated under ASC810-10-45, the ownership interest in the subsidiary that are held by owners other than the parent is a non-controlling interest. 70% held by Runteng is applying to its holding Runteng. According to the supplemental agreement signed between Junsheng Zhang and Runteng on June 01, 2013, the comprehensive income from Jiarun would be attributable to retained earnings and non-controlling interest for 70% and 30% respectively, from July 1, 2013.

SUMMARIES_OF_SIGNIFICANT_ACCOU

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES
	A.	Basis of presentation
	The consolidated financial statements have been prepared in accordance with the United States generally accepted accounting principles ("U.S. GAAP").
	B.	Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. In the opinion of management, all adjustments and normal recurring accruals considered necessary for a fair statement of the results for the period have been included.
	C.	Use of estimates
	The preparation of audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.
	D.	Functional currency and foreign currency translation
	An entity’s functional currency is the currency of the primary economic environment in which it operates, normally that is the currency of the environment in which the entity primarily generates and expends cash. Management’s judgment is essential to determine the functional currency by assessing various indicators, such as cash flows, sales price and market, expenses, financing and inter-company transactions and arrangements. The functional currency of the Company is the Renminbi (“RMB’), except Runteng paid in capital the Hong Kong Dollar (“HKD"). The reporting currency of these audited consolidated financial statements is the United States dollar (“US Dollars” or “$”).
	The financial statements of the company, which are prepared using the RMB, are translated into the Company’s reporting currency, the United States Dollar. Assets and liabilities are translated using the exchange rate at each reporting period end date. Revenue and expenses are translated using weighted average rates prevailing during each reporting period, and shareholders' equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income or expense.
	Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from these transactions are included in operations.
	The exchange rates used for foreign currency translation are as follows:
				2014	2013
				(US$ to RMB/ US$ to HKD)	(US$ to RMB)
	Assets and liabilities		period end exchange rate	6.1535/7.7580		6.114
	Revenue and expenses		period weighted average	6.1482/7.7549		6.1982
	Capital related		historical rate	6.1921		6.1921
	E.	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the years ended December 31, 2014 and December 31, 2013 respectively no and no customer accounted for more than 10% of net revenue. As of December 31, 2014 and December 31, 2013 respectively 1 and 1 customer accounted for more than 5% of net accounts receivable. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.
	F.	Cash and cash equivalents
	Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.
	G.	Accounts receivable
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
	H.	Inventories
	Inventories, consisting principally of medicines, are stated at the lower of cost or market using the first-in, first-out method (“FIFO”). This policy requires the Company to make estimates regarding the market value of inventory, including an assessment of excess or obsolete inventory. The Company determines excess or obsolete inventory based on an estimate of the future demand and estimated selling prices for its products.
	I.	Construction in progress
	Construction in progress represents the new hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress.
	J.	Property and equipment
	Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.
	Buildings and improvement		10-40 years
	Medical equipment		5-15 years
	Transportation instrument		5-10 years
	Office equipment		5-10 years
	Electronic equipment		5-10 years
	Software		5-10 years
	K.	Leases
	Operating lease
	Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.
	Capital lease
	When the lease term is equal to 75 percent or more of the estimated economic life of the leased property, the lease is classified as a capital lease, where the lessee assumes substantially all the benefits and risks of ownership. The depreciation is calculated on a straight-line basis over the estimated useful lives of leased property.
	In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation.
	L.	Fair Value Measurement
	The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.
	Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.
	ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	There were no transfers between level 1, level 2 or level 3 measurements for the years ended December 31, 2014 and 2013.
	Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.
	M.	Segment and geographic information
	The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.
	N.	Revenue recognition
	The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.
	Medicine sales
	Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.
	Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.
	Patient Services
	In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.
	Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.
	The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.
	Patients who are not covered by social insurance are liable for the total cost of medical treatment.
		l	For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.
		l	For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.
During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.
When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.
Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.
Settlement process
The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.
	l	The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.
	l	At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.
	l	The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.
O.	Income taxes
The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.
The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated financial statements.
Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income.
Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $2,157 and $1,984 for the years ended December 31, 2014 and 2013, respectively to support the local tax bureau's economical obligations.
P.	Earnings per share
Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.
Q.	Recently accounting pronouncements
From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

Accounts_Receivable_Net

Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Financing Receivables [Text Block]	NOTE 3. Accounts Receivable, Net
		December 31
		2014		2013
	Accounts receivable	$	688,885	$	298,823
	Less: allowance for doubtful debts		27,220		27,396
		$	661,665	$	271,427
	The Company experienced nil bad debts during the years ended December 31, 2014 and 2013.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 4. Inventories
	At December 31, 2014 and 2013, inventories consist of the following:
		December 31
		2014		2013
	Western medicine	$	174,907	$	94,507
	Chinese herbal medicine		5,723		3,793
		$	180,630	$	98,300

Prepayment

Prepayment	12 Months Ended
	Dec. 31, 2014
Prepaid Expense, Current [Abstract]
Prepaid Expenses Current [Text Block]	NOTE 5. Prepayment
	At December 31, 2014 and 2013, prepayment consists of the following:
		December 31
		2014		2013
	Deposits on medical equipment	$	662,631	$	43,507
	Heating fees		-		11,061
	Others		29,171		7,004
		$	691,802	$	61,572

Construction_in_Progress

Construction in Progress	12 Months Ended
	Dec. 31, 2014
Construction In Progress [Abstract]
Construction In Progress [Text Block]	NOTE 6. Construction in Progress
	The construction in progress of the Company were $Nil and $15,346,873 as of December 31, 2014 and December 31, 2013, respectively.
		December 31
		2014		2013
	Fire protection construction costs	$	-	$	19,545
	Water pump costs		-		45,744
	Building materials porcelain		-		16,356
	Building		-		15,185,032
	Wall decoration		-		37,291
	Electric power survey and design fees		-		17,553
	Public water work		-		25,352
		$	-	$	15,346,873

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 7. Property and Equipment
	At December 31, 2014 and 2013, property and equipment, at cost, consist of:
		December 31,
		2014		2013
	Transportation equipment	$	309,099	$	231,141
	Medical equipment		4,003,566		1,463,847
	Electrical equipment		677,626		47,414
	Office equipment and other		6,234		58,696
	Buildings		15,780,963		-
	Software		87,103		2,911
	Total fixed assets at cost		20,864,591		1,804,010
	Accumulated depreciation		-532,727		-387,277
	Total fixed assets, net	$	20,331,864	$	1,416,732
	Depreciation expense was $175,303 and $116,378 for the years ended December 31, 2014 and December 31, 2013, respectively.

Capital_Lease_Obligations_and_

Capital Lease Obligations and Deposit for Capital Leases	12 Months Ended
	Dec. 31, 2014
Leases, Capital [Abstract]
Capital Lease Obligations and Deposit for Capital Leases [Text Block]	NOTE 8. Capital Lease Obligations and Deposit for Capital Leases
	On September 01, 2014, Jiarun entered into a Lease Agreement to lease medical equipment from Concham Global Finance Leasing, a third party, for a three-year period, in which Jiarun is required to make monthly payments toward the lease. The Company was also required to pay a deposit up front, which deposit will later be used to offset against the last quarterly payment. The medical equipment will be transferred to Jiarun upon the completion of the Agreement.
	On October 22, 2014, Jiarun entered into a Lease Agreement to lease medical equipment and elevator from Yuandong International Leasing Company, a third party, for a three-year period, in which Jiarun is required to make monthly payments toward the lease. The Company also was required to pay a deposit up front, which deposit will be later used to offset against the last quarterly payment. The medical equipment will be transferred to Jiarun upon the completion of the Agreement.
	On June 5, 2013, Jiarun entered into a Lease Agreement to lease hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. The Leasing terms consist of principal plus 30 payments. Each payments will be made on an annual basis when 7 million RMB per payment will be paid upfront for each leasing period. The first payment was made on September 1st, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for the leasee to pay 3 million RMB as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to the Leasee (Jiarun hospital).
	According to the Financial Leasing Contract, Jiarun has committed CNY 3 million ($490,677) of premium for lease which shall be paid in full prior to commencement of the leasing period to the Leasor. In accordance to accounting principles and treatment, this payment was booked as deposit in our accounts. The Leasor shall return the premium for lease to the Leasee at expiration of this Contract, or pledge this deposit as part of rents for the last period or periods in 2043.
	The leasing agreement for our hospital building contains the following provisions:
		•	Rental payments of $1,144,913 per year, payable at the beginning of the month, September 2014.
		•	An option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the company
		•	A guarantee by the company that the lessor will realize $Nil, from selling the asset at the expiration of the lease This lease is a capital lease because its term (30 years) exceeds 75% of the building’s estimated economic life. In addition, the present value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295).
		•	Accumulated annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each year. The lease obligation is increased by the amount of the prior year’s interest, the amount of the net rental payment at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.
	These leases have been classified as capital leases. The cost of the medical equipment included in these leases is included in the consolidated balance sheets as property and equipment and construction in progress.
	The future minimum lease payments for annual capital lease obligation as of December 31, 2014 are as follows:
	Year		Amounts
	2015		$	807,478
	2016			829,630
	2017			736,771
	Thereafter			14,336,810
	Total		$	16,710,689
	The Company recorded finance lease fees of $1,007,743 and $10,661for the years ended December, 2014 and 2013, respectively.

Shortterm_Bank_Loans

Short-term Bank Loans	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Short-term Debt [Text Block]	NOTE 9. Short-term Bank Loans
		December 31
		2014		2013
	Short- term bank loans	$	471,277	$	-
	As of December 31, 2014, the above bank loans were for working capital and capital expenditure purposes. The loans were primarily obtained from Harbin Bank with interest rate of 7.84% per annum, from December 2, 2014 to December 1, 2015.The interest expenses were $1,644 and nil for the years ended December 31, 2014 and 2013, respectively.

Noncontrolling_Interests

Non-controlling Interests	12 Months Ended
	Dec. 31, 2014
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	NOTE 10. Non-controlling Interests
	Non-controlling interests represent the portion of equity in a subsidiary not attributable, directly or indirectly, to a parent. The Company’s accompanying consolidated financial statements include all assets, liabilities, revenues and expenses at their consolidated amounts, which include the amounts attributable to the Company and the non-controlling interest. The Company recognizes as a separate component of equity and earnings the portion of income or loss attributable to non-controlling interests based on the portion of the entity not owned by the Company.
	The Company adopted the provisions of FASB authoritative guidance regarding non-controlling interests in consolidated financial statements. The guidance requires the Company to clearly identify and present ownership interests in subsidiaries held by parties other than the Company in the consolidated financial statements within the equity section. It also requires the amounts of consolidated net earnings attributable to the Company and to the non-controlling interests to be clearly identified and presented on the face of the consolidated statements of operations.
	On June 01, 2013, Junsheng Zhang, the owner of Jiarun Hospital, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In which, the retained earnings of Jiarun will be 100% attributed to Junsheng Zhang up to June 30, 2013. From July 1, 2013, the income of operations from Jiarun will be attributed to Runteng and Junsheng Zhang for 70% and 30% respectively.
	On June 03, 2013, Jiarun Hospital received paid in capital of $702,508 (RMB4.35 Million) in cash from Mr. Junsheng Zhang, which has been certified by Heilongjiang Jinyuda Accountants Business Office Co. Ltd; the report number is (2013) A436.
	$702,508 are reflected under “Cash and cash equivalents” of the caption in the consolidated balance sheets.
	According to the regulation of the State Administration for Industry & Commerce of the People’s Republic of China and the shareholder investment confirmation letter signed on July 25, 2014 confirmed by both parties (Runteng Group and Junsheng Zhang), total contribution amount of Junsheng Zhang has been completed before the merger and acquisition of Runteng Group to Jiarun Hospital on June 30, 2013. Thus, Junsheng Zhang has already fulfilled his “cooperation restructuring” obligation. Both parties have confirmed Junsheng Zhang has completed his investment, no further obligations to be fulfilled by Junsheng Zhang.
	On July 08, 2014, Jiarun have obtained joint venture business license. The Company has already completed “cooperation restructuring”. According to the amending of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay $5,555,556 (35m RMB) within five years after the issuance of the joint venture business license. However, no interest is required to be paid. However, no interest is required to be paid. Up to completion of the Company’s legal structures, we are compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.
	On June 01, 2013, Junsheng Zhang, the owner of Jiarun Hospital, entered into supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In which, the retained earnings of Jiarun will be attributed to Junsheng Zhang up to June 30, 2013. From July 1, 2013, the income of operations from Jiarun will be attributed to Runteng and Junsheng Zhang for 70% and 30% respectively.
	According to the joint venture supplemental agreement, the comprehensive income of Jiarun will be attributable to the non-controlling interest up to June 30, 2013. From July 1, 2013, the comprehensive income from Jiarun will be attributable to retained earnings and non-controlling interest for 70% and 30% respectively.
	Based on the Company’s analysis of the guidance contained in FASB ASC 805-50-15 a., an example of transactions between entities under common control includes an entity that “charters” a newly formed entity and then transfers some or all of its net assets to that newly formed entity. In this situation, the Predecessor’s management (Jiarun) created the JHCC, and operating with the approval and at the direction of JHCC. For the purpose of contributing the net assets in the Predecessor, in exchange for equity in the JHCC.
	On 20th of December, 2013, by and among JRSIS HEALTH CARE CORPORATION (the “JHCC”) and JRSIS HEALTH CARE LIMITED (the “JHCL”) and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song has entered a share exchange agreement. JHCC desires to issue a total of 12,000,000 shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in exchange for one hundred percent (100%) of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC a total of 50,000 shares of the ordinary share of JHCL which represents one hundred percent (100%) of the issued and outstanding shares of JHCL. JHCL shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and an assets of JHCL as now or hereafter existing, including all business and assets of any and all subsidiaries of JHCL., including Runteng Medical Group Company Limited, a Hong Kong registered investment company that holds a seventy percent (70%) ownership interest in Harbin Jiarun Hospital Company Ltd., a Heilongjiang registered company. The Company will account for the December 2013 exchange transaction in accordance with standards promulgated by the FASB regarding transactions between entities under common control, ASC 805-50-15.
	JHCC as a parent company is subjecting ASC810-10-10, which states that consolidated financial statements are required for a fair presentation if one of the entities in the consolidated group directly or indirectly has a controlling financial interest in the other entities.
	30% of Jiarun hospital interest held by Junsheng Zhang is subjecting to non-controlling interest (“NCI”), which was stated under ASC810-10-45, the ownership interest in the subsidiary that are held by owners other than the parent is a non-controlling interest. On the other hand, 82% held by Junsheng Zhang is applying to our parent company JHCC.
	As of December 31, 2014 and 2013, NCI in the consolidated balance sheet was $2,996,434 and $2,671,064, respectively. For the year ended December 31, 2014, the comprehensive income attributable to shareholders’ equity and NCI is $601,680 and $325,370 respectively. For the year ended December 31, 2013, the comprehensive income attributable to shareholders’ equity and NCIs is $423,836 and $960,642, respectively.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2014
Revenues [Abstract]
Health Care Organization Revenues Disclosure [Text Block]	NOTE 11. Revenue
	The Company’s revenue consists of medicine sales and patient care revenue.
		For the Year Ended December 31,
		2014		2013
	Medicine:
	Western medicine	$	2,456,201	$	1,760,281
	Chinese medicine		414,188		266,064
	Herbal medicine		67,592		58,147
	Total medicine	$	2,937,981	$	2,084,492
	Patient services:
	Medical consulting	$	1,186,426	$	690,697
	Medical treatment		1,715,698		1,506,359
	Others		139,505		69,688
	Total patient services	$	3,041,629	$	2,266,744
		$	5,979,610	$	4,351,236

Income_Tax_Expense

Income Tax Expense	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 12. Income Tax Expense
	The Company uses the asset-liability method of accounting for income taxes prescribed by ASC 740 Income Taxes. The Company and its subsidiaries each files their taxes individually.
	United States
	JHCC is subject to the United States of America Tax law at tax rate of 34%. No provision for the US federal income taxes has been made as the Company had no US taxable income for the periods presented, and its earnings are permanently invested in PRC.
	BVI
	JHCL was incorporated in the BVI and, under the current laws of the BVI, it is not subject to income tax.
	Hong Kong
	Runteng was incorporated in Hong Kong and is subject to Hong Kong profits tax. Runteng is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%.
	PRC
	Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
	Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
	In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $2,157 and $1,984 for the years ended December 31, 2014 and 2013, respectively to support the local tax bureau's economical obligations.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 13. Related Party Transactions
	A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.
	As of December 31, 2014 and 2013, the Company has an accounts payable balance due to Heilongjiang Dahua Medicine Wholesale Co., Ltd owned by Junsheng Zhang, for the amount of $94,680 and $Nil, respectively.
	During the years ended December 31, 2014 and 2013, the Company purchased from Heilongjiang Dahua Medicine Wholesale Co., Ltd for $302,793 and $240,879, respectively.
	As of December 31, 2014 and 2013, the Company has a balance due to Harbin Jiarun Pharmacy Co., Limited owned by Junsheng Zhang, of $86,812 and $Nil, respectively.
	During the years ended December 31, 2014 and 2013, the Company purchased from Harbin Jiarun Pharmacy Co., Limited for $254,946 and $203,617, respectively.
	As of December 31, 2014 and December 31, 2013, the Company has a balance due to Heilongjiang Province Runjia Medical Equipment Company Limited owned by Junsheng Zhang of $107,987 and $Nil, respectively.
	During the years ended December 31, 2014 and 2013, the Company had purchased from Heilongjiang Province Runjia Medical Equipment Company Limited for $43,292 and $117,986, respectively.
	During the years ended December 31, 2014 and 2013, the Company had borrowed from Heilongjiang Province Runjia Medical Equipment Company Limited for $154,384 and $Nil, respectively.
	As of December 31, 2014 and December 31, 2013, the Company has a balance due to Jiarun Super Market Co., Ltd owned by Junsheng Zhang of $877,549 and $Nil.
	During the years ended December 31, 2014 and 2013, the Company had borrowed from Jiarun Super Market Co., Ltd owned by Junsheng Zhang for $877,549 and $Nil, respectively.
	As of December 31, 2014 and December 31, 2013, the Company has a balance due to Harbin Qi-run pharmacy limited owned by Junsheng Zhang of $130,007 and $Nil.
	During the years ended December 31, 2014 and 2013, the Company had borrowed from Harbin Qi-run pharmacy limited owned by Junsheng Zhang for $130,007 and $Nil, respectively.
	As of December 31, 2014 and December 31, 2013, the Company has a balance due to Junsheng Zhang for the amount of $3,162 and $162.
	The Company has a total balance due to related parties of $1,297,036 and $Nil as of December 31, 2014 and December 31, 2013, respectively.
	As of December 31, 2014 and December 31, 2013, the shareholder of JHCL owed the company $50,000 and $50,000 for paid-in capital respectively.
	On June 5, 2013, Jiarun entered into a Lease Agreement to lease new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. As of December 31, 2014, Harbin Baiyi Real Estate Development Co., Ltd received decoration fee paid in advance from the Company in the total amount of $135,391. As of December 31, 2014, the company has balance of deposits for capital leases and Capital lease obligations of $487,527 and $14,927,776 respectively.

Basic_and_Diluted_Earnings_Per

Basic and Diluted Earnings Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	NOTE 14.  Basic and Diluted Earnings Per Share
	Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share based awards, using the treasury stock method. The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows:
		December 31
		2014		2013
	Numerator:
	Net income available to common stockholders	$	611,494	$	399,977
	Denominator:
	Basic weighted-average number of shares outstanding		13,494,129		1,380,822
	Effect of dilutive warrants		-		-
	Diluted weighted-average number of shares outstanding		13,494,129		1,380,822
	Net income per share:
	Basic	$	0.0453	$	0.2897
	Diluted	$	0.0453	$	0.2897

Contingencies_and_Commitment

Contingencies and Commitment	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 15. Contingencies and Commitment
	Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. There was no contingency of this type as of December 31, 2014 and 2013.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. There was no contingency of this type as of December 31, 2014 and 2013.
	Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	NOTE 16. Subsequent Events
	From January 1, 2015 to March 31, 2015 there were 311,000 shares of the Company’s common stock issued and outstanding held by 12 shareholders.
	As of March 31, 2015, there were 13,915,000 shares of the Company’s common stock issued and outstanding held by 101 shareholders.
	The Management of the Company determined that there were no other reportable subsequent events to be disclosed.

SUMMARIES_OF_SIGNIFICANT_ACCOU1

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	A.	Basis of presentation
	The consolidated financial statements have been prepared in accordance with the United States generally accepted accounting principles ("U.S. GAAP").
Consolidation, Policy [Policy Text Block]	B.	Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. In the opinion of management, all adjustments and normal recurring accruals considered necessary for a fair statement of the results for the period have been included.
Use of Estimates, Policy [Policy Text Block]	C.	Use of estimates
	The preparation of audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	D.	Functional currency and foreign currency translation
	An entity’s functional currency is the currency of the primary economic environment in which it operates, normally that is the currency of the environment in which the entity primarily generates and expends cash. Management’s judgment is essential to determine the functional currency by assessing various indicators, such as cash flows, sales price and market, expenses, financing and inter-company transactions and arrangements. The functional currency of the Company is the Renminbi (“RMB’), except Runteng paid in capital the Hong Kong Dollar (“HKD"). The reporting currency of these audited consolidated financial statements is the United States dollar (“US Dollars” or “$”).
	The financial statements of the company, which are prepared using the RMB, are translated into the Company’s reporting currency, the United States Dollar. Assets and liabilities are translated using the exchange rate at each reporting period end date. Revenue and expenses are translated using weighted average rates prevailing during each reporting period, and shareholders' equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income or expense.
	Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from these transactions are included in operations.
	The exchange rates used for foreign currency translation are as follows:
				2014	2013
				(US$ to RMB/ US$ to HKD)	(US$ to RMB)
	Assets and liabilities		period end exchange rate	6.1535/7.7580		6.114
	Revenue and expenses		period weighted average	6.1482/7.7549		6.1982
	Capital related		historical rate	6.1921		6.1921
Concentration Risk, Credit Risk, Policy [Policy Text Block]	E.	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the years ended December 31, 2014 and December 31, 2013 respectively no and no customer accounted for more than 10% of net revenue. As of December 31, 2014 and December 31, 2013 respectively 1 and 1 customer accounted for more than 5% of net accounts receivable. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.
Cash and Cash Equivalents, Policy [Policy Text Block]	F.	Cash and cash equivalents
	Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	G.	Accounts receivable
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Inventory, Policy [Policy Text Block]	H.	Inventories
	Inventories, consisting principally of medicines, are stated at the lower of cost or market using the first-in, first-out method (“FIFO”). This policy requires the Company to make estimates regarding the market value of inventory, including an assessment of excess or obsolete inventory. The Company determines excess or obsolete inventory based on an estimate of the future demand and estimated selling prices for its products.
Construction In Progress [Policy Text Block]	I.	Construction in progress
	Construction in progress represents the new hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress.
Property, Plant and Equipment, Policy [Policy Text Block]	J.	Property and equipment
	Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.
	Buildings and improvement		10-40 years
	Medical equipment		5-15 years
	Transportation instrument		5-10 years
	Office equipment		5-10 years
	Electronic equipment		5-10 years
	Software		5-10 years
Lease, Policy [Policy Text Block]	K.	Leases
	Operating lease
	Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.
	Capital lease
	When the lease term is equal to 75 percent or more of the estimated economic life of the leased property, the lease is classified as a capital lease, where the lessee assumes substantially all the benefits and risks of ownership. The depreciation is calculated on a straight-line basis over the estimated useful lives of leased property.
	In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation.
Fair Value Measurement, Policy [Policy Text Block]	L.	Fair Value Measurement
	The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.
	Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.
	ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	There were no transfers between level 1, level 2 or level 3 measurements for the years ended December 31, 2014 and 2013.
	Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.
Segment Reporting, Policy [Policy Text Block]	M.	Segment and geographic information
	The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the company are located in PRC.
Revenue Recognition, Policy [Policy Text Block]	N.	Revenue recognition
	The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.
	Medicine sales
	Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.
	Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.
	Patient Services
	In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.
	Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.
	The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.
	Patients who are not covered by social insurance are liable for the total cost of medical treatment.
		l	For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.
		l	For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.
	During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.
	When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.
	Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.
	Settlement process
	The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.
		l	The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.
		l	At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.
		l	The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.
Income Tax, Policy [Policy Text Block]	O.	Income taxes
	The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
	In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48(ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.
	The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
	As a result of the implementation of FIN 48 (ASC 740-10), the company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s unaudited consolidated financial statements.
	Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income.
	Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.
	Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.
	In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $2,157 and $1,984 for the years ended December 31, 2014 and 2013, respectively to support the local tax bureau's economical obligations.
Earnings Per Share, Policy [Policy Text Block]	P.	Earnings per share
	Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.
New Accounting Pronouncements, Policy [Policy Text Block]	Q.	Recently accounting pronouncements
	From time to time, new accounting standards issued by the Financial Accounting Standards Board (“FASB”) are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

SUMMARIES_OF_SIGNIFICANT_ACCOU2

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount [Table Text Block]	The exchange rates used for foreign currency translation are as follows:
			2014	2013
			(US$ to RMB/ US$ to HKD)	(US$ to RMB)
	Assets and liabilities	period end exchange rate	6.1535/7.7580		6.114
	Revenue and expenses	period weighted average	6.1482/7.7549		6.1982
	Capital related	historical rate	6.1921		6.1921
Property Plant And Equipment Useful Life [Table Text Block]	When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.
	Buildings and improvement	10-40 years
	Medical equipment	5-15 years
	Transportation instrument	5-10 years
	Office equipment	5-10 years
	Electronic equipment	5-10 years
	Software	5-10 years

Accounts_Receivable_Net_Tables

Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]		December 31
		2014		2013
	Accounts receivable	$	688,885	$	298,823
	Less: allowance for doubtful debts		27,220		27,396
		$	661,665	$	271,427

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	At December 31, 2014 and 2013, inventories consist of the following:
		December 31
		2014		2013
	Western medicine	$	174,907	$	94,507
	Chinese herbal medicine		5,723		3,793
		$	180,630	$	98,300

Prepayment_Tables

Prepayment (Tables)	12 Months Ended
	Dec. 31, 2014
Prepaid Expense, Current [Abstract]
Schedule Of Prepaid Expenses Current [Table Text Block]	At December 31, 2014 and 2013, prepayment consists of the following:
		December 31
		2014		2013
	Deposits on medical equipment	$	662,631	$	43,507
	Heating fees		-		11,061
	Others		29,171		7,004
		$	691,802	$	61,572

Construction_in_Progress_Table

Construction in Progress (Tables)	12 Months Ended
	Dec. 31, 2014
Construction In Progress [Abstract]
Schedule Of Construction In Progress [Table Text Block]	The construction in progress of the Company were $Nil and $15,346,873 as of December 31, 2014 and December 31, 2013, respectively.
		December 31
		2014		2013
	Fire protection construction costs	$	-	$	19,545
	Water pump costs		-		45,744
	Building materials porcelain		-		16,356
	Building		-		15,185,032
	Wall decoration		-		37,291
	Electric power survey and design fees		-		17,553
	Public water work		-		25,352
		$	-	$	15,346,873

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	At December 31, 2014 and 2013, property and equipment, at cost, consist of:
		December 31,
		2014		2013
	Transportation equipment	$	309,099	$	231,141
	Medical equipment		4,003,566		1,463,847
	Electrical equipment		677,626		47,414
	Office equipment and other		6,234		58,696
	Buildings		15,780,963		-
	Software		87,103		2,911
	Total fixed assets at cost		20,864,591		1,804,010
	Accumulated depreciation		-532,727		-387,277
	Total fixed assets, net	$	20,331,864	$	1,416,732

Capital_Lease_Obligations_and_1

Capital Lease Obligations and Deposit for Capital Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Leases, Capital [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The future minimum lease payments for annual capital lease obligation as of December 31, 2014 are as follows:
	Year	Amounts
	2015	$	807,478
	2016		829,630
	2017		736,771
	Thereafter		14,336,810
	Total	$	16,710,689

Shortterm_Bank_Loans_Tables

Short-term Bank Loans (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Short-term Debt [Table Text Block]		December 31
		2014		2013
	Short- term bank loans	$	471,277	$	-

Revenue_Tables

Revenue (Tables)	12 Months Ended
	Dec. 31, 2014
Revenues [Abstract]
Schedule Of Health Care Organization Revenues [Table Text Block]	The Company’s revenue consists of medicine sales and patient care revenue.
		For the Year Ended December 31,
		2014		2013
	Medicine:
	Western medicine	$	2,456,201	$	1,760,281
	Chinese medicine		414,188		266,064
	Herbal medicine		67,592		58,147
	Total medicine	$	2,937,981	$	2,084,492
	Patient services:
	Medical consulting	$	1,186,426	$	690,697
	Medical treatment		1,715,698		1,506,359
	Others		139,505		69,688
	Total patient services	$	3,041,629	$	2,266,744
		$	5,979,610	$	4,351,236

Basic_and_Diluted_Earnings_Per1

Basic and Diluted Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows:
		December 31
		2014		2013
	Numerator:
	Net income available to common stockholders	$	611,494	$	399,977
	Denominator:
	Basic weighted-average number of shares outstanding		13,494,129		1,380,822
	Effect of dilutive warrants		-		-
	Diluted weighted-average number of shares outstanding		13,494,129		1,380,822
	Net income per share:
	Basic	$	0.0453	$	0.2897
	Diluted	$	0.0453	$	0.2897

DESCRIPTION_OF_BUSINESS_AND_OR1

DESCRIPTION OF BUSINESS AND ORGANIZATION (Details Textual)

12 Months Ended

1 Months Ended

0 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 20, 2013

Feb. 25, 2013

Nov. 08, 2013

Oct. 03, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2014

Oct. 03, 2013

Nov. 08, 2013

Oct. 03, 2013

Dec. 31, 2014

Jun. 30, 2013

Dec. 23, 2012

Dec. 23, 2012

Jul. 08, 2014

Jul. 08, 2014

Jul. 29, 2013

Nov. 20, 2013

Dec. 31, 2013

Dec. 31, 2014

Feb. 25, 2013

Mar. 07, 2013

Dec. 23, 2012

Sep. 17, 2012

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2014

Sep. 17, 2012

USD ($)

USD ($)

Share Exchange Agreement [Member]

Ms. Yanhua Xing [Member]

Non-controlling interest, Junsheng Zhang [Member]

Non-controlling interest, Junsheng Zhang [Member]

Non-controlling interest, Junsheng Zhang [Member]

Non-controlling interest, Junsheng Zhang [Member]

Non-controlling interest, Junsheng Zhang [Member]

Chunlan Tang [Member]

Weiguang Song [Member]

Weiguang Song [Member]

Subsidiary, Harbin Jiarun Hospital Co., Ltd [Member]

Subsidiary, Harbin Jiarun Hospital Co., Ltd [Member]

Subsidiary, Harbin Jiarun Hospital Co., Ltd [Member]

Subsidiary, Harbin Jiarun Hospital Co., Ltd [Member]

Runteng [Member]

Runteng [Member]

Runteng [Member]

Subsidiary, JRSIS HEALTH CARE LIMITED [Member]

Subsidiary, JRSIS HEALTH CARE LIMITED [Member]

Subsidiary, JRSIS HEALTH CARE LIMITED [Member]

Subsidiary, JRSIS HEALTH CARE LIMITED [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

Subsidiary, Runteng Medical Group Co., Ltd [Member]

USD ($)

USD ($)

USD ($)

USD ($)

CNY

USD ($)

CNY

Non-controlling interest, Junsheng Zhang [Member]

USD ($)

USD ($)

Ms. Yanhua Xing [Member]

USD ($)

HKD

USD ($)

HKD

Mary Xing [Member]

Business And Organization [Line Items]

Common Stock, Shares Authorized

100,000,000

100,000,000

50,000

50,000

10,000

10,000

10,000

Common Stock, Par or Stated Value Per Share

$0.00

$0.00

$1

$1

1

1

Joint venture investment in Jiarun, Ownership Percentage in Harbin Jiarun Hospital Co., Ltd

70.00%

Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions

$921,000

Common Stock, Shares, Issued

13,604,000

12,000,000

50,000

50,000

50,000

100

100

100

Unrecorded Unconditional Purchase Obligation

5,555,556

35,000,000

Joint venture investment in jiarun, Capital Investment Agreement Term

5 years

JHCL acquired all shares of Runteng Medical Group Co., Ltd, JHCl's Shares

100

Shares Transferred Under Transaction

50,000

Shares, Outstanding

100

Common Stock, Capital Shares Reserved for Future Issuance

12,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

30.00%

Entity Incorporation, Date of Incorporation

20-Nov-13

25-Feb-13

17-Sep-12

Variable Interest Entity, Qualitative or Quantitative Information, Nature of VIE

privately held, for-profit hospital

Related Party Transaction, Terms and Manner of Settlement

Joint Venture Jiarun duration of operation is twenty years.

Common Stock, Shares, Outstanding

13,604,000

12,000,000

50,000

50,000

100

100

100

Shares Transferred Under Transaction and Shares Exchange, Shares

46,500

23,275

23,225

1,050

1,050

50,000

50,000

Joint Venture Investment Obligation To Pay Capital

2,380,952

15,000,000

5,555,556

Joint Venture Investment Additional Paid Up Capital

921,000

921,000

[1]

0

Attribution of accumulated retained earnings of Jiarun, Percentage

30.00%

100.00%

30.00%

70.00%

70.00%

0.00%

70.00%

Attribution of accumulated retained earnings of Jiarun, Agreement date

1-Jun-13

Joint venture investment in jiarun, Registered Capital

$7,936,508

[1]

50,000,000

[1]

[1]

Harbin Jiarun Hospital Co., Ltd is a privately held, for-profit hospital

SUMMARIES_OF_SIGNIFICANT_ACCOU3

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
	Assets and liabilities [Member]	Assets and liabilities [Member]	Assets and liabilities [Member]	Revenue and expenses [Member]	Revenue and expenses [Member]	Revenue and expenses [Member]	Capital related [Member]	Capital related [Member]
	period end exchange rate [Member]	period end exchange rate [Member]	period end exchange rate [Member]	period weighted average [Member]	period weighted average [Member]	period weighted average [Member]	historical rate [Member]	historical rate [Member]
	CNY	HKD	CNY	CNY	HKD	CNY	CNY	CNY
Foreign Currency Exchange Rates Translation	6.1535	7.758	6.114	6.1482	7.7549	6.1982	6.1921	6.1921

SUMMARIES_OF_SIGNIFICANT_ACCOU4

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	12 Months Ended
	Dec. 31, 2014
Buildings and improvement [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Buildings and improvement [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Medical equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Medical equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Transportation instrument [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Transportation instrument [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Office equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Electronic equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Electronic equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

SUMMARIES_OF_SIGNIFICANT_ACCOU5

SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Paid	($2,157)	($1,984)
Effective Income Tax Rate Reconciliation, Percent	25.00%	25.00%
Accounts Receivable [Member]
Concentration Risk, Percentage	5.00%	5.00%

Accounts_Receivable_Net_Detail

Accounts Receivable, Net (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$688,885	$298,823
Less: allowance for doubtful debts	27,220	27,396
Accounts Receivable, Net, Current	$661,665	$271,427

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Inventory, Net	$180,630	$98,300
Western medicine [Member]
Inventory [Line Items]
Inventory, Net	174,907	94,507
Chinese herbal medicine [Member]
Inventory [Line Items]
Inventory, Net	$5,723	$3,793

Prepayment_Details

Prepayment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Prepaid Expenses Current [Line Items]
Prepaid Expense, Current	$691,802	$61,572
Deposits on medical equipment [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Prepaid Expense, Current	662,631	43,507
Heating fees [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Prepaid Expense, Current	0	11,061
Others [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Prepaid Expense, Current	$29,171	$7,004

Construction_in_Progress_Detai

Construction in Progress (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	$0	$15,346,873
Fire protection construction costs [Member]
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	0	19,545
Water pump costs [Member]
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	0	45,744
Building materials porcelain [Member]
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	0	16,356
Building [Member]
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	0	15,185,032
Wall decoration [Member]
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	0	37,291
Electric power survey and design fees [Member]
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	0	17,553
Public water work [Member]
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	$0	$25,352

Construction_in_Progress_Detai1

Construction in Progress (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Construction In Progress [Line Items]
Construction in Progress, Gross	$0	$15,346,873

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	$20,864,591	$1,804,010
Accumulated depreciation	-532,727	-387,277
Total fixed assets, net	20,331,864	1,416,732
Transportation equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	309,099	231,141
Medical equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	4,003,566	1,463,847
Electrical equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	677,626	47,414
Office equipment and other [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	6,234	58,696
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	15,780,963	0
Software [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	$87,103	$2,911

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$175,303	$116,378

Capital_Lease_Obligations_and_2

Capital Lease Obligations and Deposit for Capital Leases (Details) (USD $)	Dec. 31, 2014
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
2015	$807,478
2016	829,630
2017	736,771
Thereafter	14,336,810
Total	$16,710,689

Capital_Lease_Obligations_and_3

Capital Lease Obligations and Deposit for Capital Leases (Details Textual)	Dec. 31, 2014	Dec. 31, 2013	Sep. 01, 2014	Oct. 22, 2014	Jun. 05, 2013	Jun. 05, 2013
	USD ($)	USD ($)	Concham Global Finance Leasing [Member]	Yuandong International Leasing Company [Member]	Harbin Baiyi Real Estate Development Co., Ltd [Member]	Harbin Baiyi Real Estate Development Co., Ltd [Member]
					USD ($)	CNY
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
Lease Agreement Annual Payments					$1,144,913	7,000,000
Captial Lease Obligation Deposits (Financial Leasing Premium Payments)					490,677	3,000,000
Term of Capital Lease			3 years	3 years	30 years	30 years
Capital Lease Obligation Interest Rate Percentage					6.55%	6.55%
Capital Lease Future Minimum Payments Fair Value Of Assets					15,721,295
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments					15,185,032
Payment periods Of The Lease			monthly	monthly	annual	annual
Lease Expiration Term Description					2043	2043
Capital Leases, Net Investment in Direct Financing Leases	$1,007,743	$10,661

Shortterm_Bank_Loans_Details

Short-term Bank Loans (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Short Term Bank Loan Disclosure [Line Items]
Short-term bank loans	$471,277	$0

Shortterm_Bank_Loans_Details_T

Short-term Bank Loans (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Short-term Debt [Line Items]
Short-term Debt, Percentage Bearing Fixed Interest Rate	7.84%
Interest Expense, Debt	$1,644	$0

Noncontrolling_Interests_Detai

Non-controlling Interests (Details Textual)

6 Months Ended

12 Months Ended

0 Months Ended

6 Months Ended

12 Months Ended

18 Months Ended

6 Months Ended

6 Months Ended

18 Months Ended

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 08, 2014

Dec. 31, 2014

Dec. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2014

Jun. 30, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2014

USD ($)

USD ($)

USD ($)

Retained Earnings [Member]

Noncontrolling Interest [Member]

Runteng [Member]

Runteng [Member]

Runteng [Member]

Junsheng Zhang [Member]

Junsheng Zhang [Member]

Junsheng Zhang [Member]

Junsheng Zhang [Member]

Jiarun [Member]

Jiarun [Member]

Harbin Jiarun Hospital Company Ltd [Member]

Jiarun Hospital [Member]

Shareholders of JHCC [Member]

Runteng Medical Group Co Ltd [Member]

Runteng Medical Group Co Ltd [Member]

USD ($)

USD ($)

USD ($)

CNY

USD ($)

CNY

Retained Earnings [Member]

Noncontrolling Interest [Member]

Noncontrolling Interest [Line Items]

Capital Lease Obligation Joint Venture Investment Agreement Description

According to the amending of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay $5,555,556 (35m RMB) within five years after the issuance of the joint venture business license.

Noncontrolling Interest, Ownership Percentage by Parent

82.00%

Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest

$325,370

$960,642

Comprehensive Income (Loss), Net of Tax, Attributable to Parent

601,680

423,836

Concentration Risk, Percentage

70.00%

30.00%

Business Acquisition, Equity Interest Acquired, Number of Shares

50,000

Attribution of accumulated retained earnings of Jiarun and Profit Sharing Percentage

100.00%

30.00%

0.00%

70.00%

Additional Paid In Capital Contribution To Noncontrolling Interest

702,508

0

702,508

702,508

4,350,000

Stockholders' Equity Attributable to Noncontrolling Interest

2,671,064

2,996,434

2,671,064

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

12,000,000

Due from Joint Ventures

$5,555,556

35,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

30.00%

70.00%

30.00%

Revenue_Details

Revenue (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Product Information [Line Items]
Sales Revenue, Goods, Net	$2,937,981	$2,084,492
Sales Revenue, Services, Net	3,041,629	2,266,744
Revenue, Net	5,979,610	4,351,236
Western Medicine [Member]
Product Information [Line Items]
Sales Revenue, Goods, Net	2,456,201	1,760,281
Chinese Medicine [Member]
Product Information [Line Items]
Sales Revenue, Goods, Net	414,188	266,064
Herbal Medicine [Member]
Product Information [Line Items]
Sales Revenue, Goods, Net	67,592	58,147
Medical Consulting [Member]
Product Information [Line Items]
Sales Revenue, Services, Net	1,186,426	690,697
Medical Treatment [Member]
Product Information [Line Items]
Sales Revenue, Services, Net	1,715,698	1,506,359
Others [Member]
Product Information [Line Items]
Sales Revenue, Services, Net	$139,505	$69,688

Income_Tax_Expense_Details_Tex

Income Tax Expense (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Expense [Line Items]
Income Tax Expense (Benefit)	$2,157	$1,984
UNITED STATES
Income Tax Expense [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
HONG KONG
Income Tax Expense [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	16.50%

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Due to related parties, ended of the period	$1,297,036	$0
Heilongjiang Dahua Medicine Wholesale Co Ltd [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	94,680	0
Payment for medical supplies and drugs, during the period	302,793	240,879
Harbin Jiarun Pharmacy Co Limited [Member]
Related Party Transaction [Line Items]
Payment for medical supplies and drugs, during the period	254,946	203,617
Due to related parties, ended of the period	86,812	0
Heilongjiang Province Runjia Medical Equipment Company Limited [Member]
Related Party Transaction [Line Items]
Payment for medical supplies and drugs, during the period	43,292	117,986
Due to related parties, ended of the period	107,987	0
Proceeds from other short-term debt, during the period	154,384	0
Jiarun Super Market Co Ltd [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	877,549	0
Proceeds from other short-term debt, during the period	877,549	0
Harbin Qirun pharmacy limited [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	130,007	0
Proceeds from other short-term debt, during the period	130,007	0
Shareholder of JHCL [Member]
Related Party Transaction [Line Items]
Advance to related parties, ended of the period	50,000	50,000
Harbin Baiyi Real Estate Development Co., Ltd [Member]
Related Party Transaction [Line Items]
Deposits for capital leases, ended of the period	487,527	0
Advance to related parties, ended of the period	135,391	0
Capital lease obligations, ended of the period	14,927,776	0
Junsheng Zhang [Member]
Related Party Transaction [Line Items]
Due to related parties, ended of the period	$3,162	$162

Basic_and_Diluted_Earnings_Per2

Basic and Diluted Earnings Per Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net income available to common stockholders	$611,494	$399,977
Denominator:
Basic weighted-average number of shares outstanding	13,494,129	1,380,822
Effect of dilutive warrants	0	0
Diluted weighted-average number of shares outstanding	13,494,129	1,380,822
Net income per share:
Basic	$0.05	$0.29
Diluted	$0.05	$0.29

Contingencies_and_Commitment_D

Contingencies and Commitment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments And Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$0	$0
Loss Contingency, Estimate of Possible Loss	$0	$0

Subsequent_Events_Details_Text

Subsequent Events (Details Textual)	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Subsequent Event [Line Items]
Common Stock, Shares, Issued	13,604,000	12,000,000
Common Stock, Shares, Outstanding	13,604,000	12,000,000
12 Shareholders [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued			311,000
Common Stock, Shares, Outstanding			311,000
101 Shareholders [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued			13,915,000
Common Stock, Shares, Outstanding			13,915,000